Diabetes Care:新型1型糖尿病患者的夜间血糖管理系统显示效果良好

2017-01-22 MedSci MedSci原创

最近发表在Diabetes Care上的一项研究对高血糖和低血糖最小值预测(PHHM)系统vs低血糖胰岛素暂停预测(PLGS)系统在夜间血糖控制方面的安全性,可行性,和疗效进行了比较。该研究中共包括30名15-45岁的1型糖尿病患者,研究为期42夜。参与者被随机分配每晚接受PHHM系统或PLGS系统管理,且试验过程中研究人员不知道具体分配方案。。当PHHM系统或PLGS系统监测到低血糖时均会暂停胰

最近发表在Diabetes Care上的一项研究对高血糖和低血糖最小值预测(PHHM)系统vs低血糖胰岛素暂停预测(PLGS)系统在夜间血糖控制方面的安全性,可行性,和疗效进行了比较。

该研究中共包括30名15-45岁的1型糖尿病患者,研究为期42夜。参与者被随机分配每晚接受PHHM系统或PLGS系统管理,且试验过程中研究人员不知道具体分配方案。。当PHHM系统或PLGS系统监测到低血糖时均会暂停胰岛素泵,但是当预测到高血糖时,只有PHHM系统能智能补充胰岛素用量。主要结果是夜晚葡萄糖传感器监测到的70-180mg/dL血糖的维持时间百分比。

附加有自动胰岛素注射器的PHHM系统增加了每夜血糖控制在70-180mg/dL的时间,78%±10%(PHHM系统) vs 71%±10%(PLGS系统)(P < 0.001)。平均清晨血糖浓度:142 ± 18 mg/dL(PHHM系统) vs 163 ± 23 mg/dL(PLGS系统)(P < 0.001)。各种传感器的血糖测量结果在两个系统间是相似的。所有受试者的42夜的研究过程中没有出现严重低血糖、糖尿病酮症酸中毒、以及其他研究或设备相关的不良事件。

通过研究结果,研究人员认为,对于夜间血糖的管理,在现存的PLGS系统中加入高血糖最小值预测是安全、可行且有效的。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759850, encodeId=fde01e59850d1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 17 00:16:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901533, encodeId=3426190153301, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 04 05:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637590, encodeId=eb5b163e59091, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 03 14:16:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968208, encodeId=c18d19682083c, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jun 02 07:16:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474115, encodeId=699614e411574, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521569, encodeId=55b81521569d0, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759850, encodeId=fde01e59850d1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 17 00:16:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901533, encodeId=3426190153301, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 04 05:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637590, encodeId=eb5b163e59091, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 03 14:16:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968208, encodeId=c18d19682083c, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jun 02 07:16:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474115, encodeId=699614e411574, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521569, encodeId=55b81521569d0, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759850, encodeId=fde01e59850d1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 17 00:16:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901533, encodeId=3426190153301, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 04 05:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637590, encodeId=eb5b163e59091, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 03 14:16:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968208, encodeId=c18d19682083c, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jun 02 07:16:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474115, encodeId=699614e411574, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521569, encodeId=55b81521569d0, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759850, encodeId=fde01e59850d1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 17 00:16:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901533, encodeId=3426190153301, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 04 05:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637590, encodeId=eb5b163e59091, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 03 14:16:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968208, encodeId=c18d19682083c, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jun 02 07:16:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474115, encodeId=699614e411574, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521569, encodeId=55b81521569d0, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1759850, encodeId=fde01e59850d1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 17 00:16:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901533, encodeId=3426190153301, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 04 05:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637590, encodeId=eb5b163e59091, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 03 14:16:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968208, encodeId=c18d19682083c, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jun 02 07:16:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474115, encodeId=699614e411574, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521569, encodeId=55b81521569d0, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1759850, encodeId=fde01e59850d1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 17 00:16:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901533, encodeId=3426190153301, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 04 05:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637590, encodeId=eb5b163e59091, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 03 14:16:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968208, encodeId=c18d19682083c, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jun 02 07:16:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474115, encodeId=699614e411574, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521569, encodeId=55b81521569d0, content=<a href='/topic/show?id=3c4e8985327' target=_blank style='color:#2F92EE;'>#血糖管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89853, encryptionId=3c4e8985327, topicName=血糖管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2da11366066, createdName=zhangying8792, createdTime=Tue Jan 24 07:16:00 CST 2017, time=2017-01-24, status=1, ipAttribution=)]

相关资讯

Diabetes Care:循环中的代谢产物与糖尿病终末期肾病风险之间有何关系?

患者循环中某种修饰的代谢产物的水平能够更快的经历肾功能下降,并导致终末期肾病。这些候选代谢物是否作为危险因素或仅仅是1型糖尿病患者终末期肾病进展的预后生物标志物仍需要进一步研究确定。

糖尿病人过冬,谨记这9点!

mportant; word-wrap: break-word !important;">保持心态平和据调查,大约50%糖尿病患者存在各种各样的心理问题,许多病人容易出现情绪波动,这种情况在冬季尤为突出。而情绪激动除了能引起交感神经兴奋、血压升高之外,还可促进肝糖原分解,使血糖升高,导致病情加重或降低治疗效果。所以,糖尿病患者要学会控制情绪,尽量减少情绪波动。, 冬天,糖尿病病人抵抗力差,更易发生

糖尿病的8大危险信号!

在控糖的道路上,除了注意合理饮食、适当运动、调节心情、监测血糖外,还应留意身体的一些小变化,如果出现以下8种症状,有可能预示着并发症发生。一 视物模糊视物模糊可能是睡眠不足或用眼过度所致,也有可能预示着糖尿病视网膜病变。糖尿病的病程越长,视网膜病变的发生率越高,很多糖尿病患者只知道定期查血糖和尿糖,而不知道需要定期查眼底,发现时可能已经为糖尿病视网膜病变的后期了。二小便泡沫增多糖尿病患者

JAMA:中国城乡糖尿病患病率及死亡率

2017年1月17日,JAMA刊登了中国慢性病前瞻性研究(China Kadoorie Biobank, CKB)项目的一项研究进展,公布了中国城乡糖尿病患病率及死亡率的数据。该研究的通讯作者为英国牛津大学的陈铮鸣教授和北京大学公共卫生学院的李立明教授。 近几十年来,中国糖尿病患病率大幅增加,但是目前还缺乏糖尿病相关的超额死亡率的可靠数据。本研究对中国农村和城市地区的糖尿病相关超额死亡率进行

柳叶刀子刊:中国糖尿病研究进展

日前,《柳叶刀·糖尿病与内分泌学》杂志发表了一篇近年来中国糖尿病研究概况的论述。文章从当前中国研究重点及以后研究方向作了相关陈述。以下为详细内容:近几十年糖尿病患病率急剧增加,中国已成为糖尿病患病人数最多的国家。由于疾病负担的加重,我国开展的糖尿病研究不断增加,不仅包括基础研究还包括临床观点。研究领域也在逐渐多元化,2000年大部分研究集中于疾病临床表现,包括代谢、一般医疗问题及心脏疾病。但201

Diabetes Care:艾塞那肽与吡格列酮联合或可替代胰岛素治疗2型糖尿病(Qatar研究)

对于二甲双胍和磺脲类药物控制不佳的2型糖尿病患者,吡格列酮和胰高血糖素肽1(GLP-1)受体激动剂艾塞那肽组合可能是胰岛素安全、有效的替代治疗选择。相关研究在线发表于1月17日的《糖尿病护理》杂志上。研究结果曾在去年美国新奥尔良ADA年会上公布。艾塞那肽可改善β细胞功能,而噻唑烷二酮类药物吡格列酮可改善β细胞功能和胰岛素敏感性。两药联合可以改善2型糖尿病患者的代谢缺陷。联合治疗可带来更大血糖获益尽